RIAltO: A Randomised Investigation of Alternative Ofatumumab-containing regimens in less fit patients with CLL
Phase of Trial: Phase III
Latest Information Update: 16 Jan 2018
At a glance
- Drugs Ofatumumab (Primary) ; Bendamustine; Chlorambucil
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms RIAltO
- 12 Jan 2018 Planned End Date changed from 1 Dec 2017 to 30 Apr 2018.
- 10 Jun 2017 Biomarkers information updated
- 25 Feb 2016 Accrual to date is 65% as reported by United Kingdom Clinical Research Network.